compound 72 [WO2013026806]

Ligand id: 8166

Name: compound 72 [WO2013026806]

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 112.02
Molecular weight 369.05
XLogP 3.87
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Mechanism Of Action and Pharmacodynamic Effects
Compound 72 was developed primarily for its potential to modulate the enhanced activity of DYRK1A in Down's syndrome-related Alzheimer's disease. Additional uses covered by the patent include treatment of other neurodegenerative conditions and some cancers (specifically certain solid tumours) [5].
The DYRK1A gene is located within the Down Syndrome (DS) critical region on chromosome 21. Trisomy of chromosome 21 leads to overexpression of DYRK1A and amyloid precursor protein (APP), and this may underlie the Tau and amyloid pathologies associated with early onset Alzheimer's disease in DS [2,4,6-7]. Pharmacological inhibition of DYRK1A activity would aim to modify the course of AD pathogenesis.